What guidance did Integra Lifesciences Holdings's management provide for the next earnings period?

What were the key takeaways from Integra Lifesciences Holdings’s earnings call?

Did Integra Lifesciences Holdings beat or miss consensus estimates last quarter?

What factors drove the changes in Integra Lifesciences Holdings's revenue and profit?

What does Integra Lifesciences Holdings do and what are its main business segments?

What is Integra Lifesciences Holdings's latest dividend and current dividend yield?

What were the key takeaways from Integra Lifesciences Holdings's earnings call?

What is Integra Lifesciences Holdings's gross profit margin?

- **Revenue Growth Despite Challenges**: Q3 2025 organic revenue up 5%, driven by Neurosurgery and Wound Reconstruction, but offset by CSS supply disruptions.
- **Strategic Progress**: Relaunched PriMatrix/Durepair ahead of schedule via dual sourcing; Integra Skin yields improved 50%.
- **Cost Savings Initiative**: $25-30M 2026 savings from COGS and operating model efficiencies.
- **Financial Resilience**: Adjusted EPS beat ($0.54 vs. $0.41 prior year), despite 260bps gross margin headwinds.
- **Key Risks**: Private label partner softness, tariff impacts, and Compliance Master Plan costs weighing on margins.

**【CEO Summary Section】**
- **Revenue Performance**: Q3 2025 revenue of $402 million, reflecting 5% organic growth year-over-year, driven by strong demand in Neurosurgery and Wound Reconstruction. However, supply interruptions in CSS (Core Surgical Solutions) led to a shortfall below expectations.
- **Strategic Initiatives**: 
  - **Compliance Master Plan**: Progress on quality system improvements, including 50% yield improvement in Integra Skin and 2.5x inventory growth. PriMatrix and Durepair relaunched ahead of schedule via dual sourcing.
  - **Operational Excellence**: $25-30 million cost savings expected in 2026 through COGS optimization and operating model efficiencies.
  - **Product Pipeline**: SurgiMend production to resume in June 2026, targeting Q4 2026 launch. DuraSorb and Integra Skin growth offset MediHoney declines.

**【CFO Financial Commentary】**
- **Financial Highlights**: 
  - Adjusted EPS of $0.54 (vs. $0.41 prior year), exceeding guidance due to cost control.
  - Gross margin 62.9% (down 10bps YoY) due to remediation costs and tariffs, partially offset by higher-margin product mix.
  - Operating cash flow $41 million, free cash flow $25.8 million, reflecting improved liquidity management.
- **Guidance Update**: 
  - Full-year 2025 revenue $1.62-1.64 billion (0.6%-1.8% reported growth), adjusted EPS $2.19-2.24.
  - Q4 2025 revenue $420-440 million (5%-0.6% decline), EPS $0.79-0.84.
- **Key Drivers**: Entrenched supply chain challenges, private label partner softness, and tariff headwinds offset by disciplined expense management.

**【Q&A Key Highlights】**
- **Supply Chain Challenges**: Q3 CSS interruptions resolved, but Q4 performance constrained by production ramp rates and market seasonality.
- **Private Label Risks**: Ongoing softness from key partner, expected to stabilize in low single digits in 2026.
- **Gross Margin Outlook**: 2025 gross margin decline of ~260bps (200bps from remediation, 60bps from tariffs). 2026 margin stabilization contingent on supply chain normalization.
- **Product Relaunch Momentum**: PriMatrix/Durepair relaunch ahead of schedule, with early physician feedback positive. SurgiMend launch in Q4 2026 on track.
- **Leverage Management**: 2025 leverage ratio 4.3x, targeting reduction in 2026 through EBITDA growth and debt repayment.

Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript

- **Compliance Progress**: All manufacturing sites assessed; no new shipholds. Remediation efforts extend into 2026, with $100M full-year impact.
- **Revenue Beat**: Q2 revenue $415.6M (high-end guidance). Full-year updated to $1.655B-$1.68B, driven by Q4 supply recovery.
- **Cost Savings Initiative**: $25M-$30M annualized savings target over 12-18 months.
- **Integra Skin Momentum**: Record production levels; normal revenue run rate expected through 2025.
- **Tariff Impact**: Q4 EPS headwind $0.13, with longer-term mitigation strategies in place.

**【CEO Summary Section】**
- **Compliance Master Plan Progress**: All internal manufacturing sites assessed ahead of schedule with no new shipholds identified. Remediation planning underway, with some efforts extending into 2026. Positive FDA inspection outcomes at 2 facilities not under warning letters.
- **Operational Excellence**: New supply chain control tower implemented. Braintree facility on track for 2026 relaunch of SurgiMend and PriMatrix; production of Integra Skin at record levels.
- **Financial Results**: Q2 revenue $415.6M (beat high-end guidance), adjusted EPS $0.45. Full-year revenue guidance updated to $1.655B-$1.68B, reflecting $100M shiphold impact. Q3 revenue expected $410M-$420M, with Q4 step-up driven by seasonal demand and supply recovery.
- **Strategic Initiatives**: $25M-$30M annualized cost savings target over 12-18 months. Focus on clinical evidence to support broader reimbursement for wound reconstruction products.

**【CFO Financial Commentary】**
- **Q2 Financials**: GAAP net loss $511M (goodwill impairment charge), adjusted EPS $0.45. Gross margin 60.7% (-450bps YoY) due to remediation costs. Adjusted EBITDA margin 17.1% (-290bps YoY).
- **Segment Performance**: 
  - **CSS (Codman Specialty Surgical)**: Revenue $304M (0.7% reported growth). Neurosurgery franchises strong, ENT growth below expectations due to reimbursement pressures.
  - **Tissue Technology**: Revenue $111.6M (-4% YoY). Integra Skin production at record levels, offsetting MediHoney shiphold impact.
- **Liquidity**: $1.1B total liquidity, $1.59B net debt. Q2 operating cash flow $8.9M.
- **Tariffs**: Q2 impact $0.13 EPS, with $0.13 expected in Q4. Longer-term mitigation strategies underway.

**【Q&A Key Highlights】**
- **CMS Reimbursement Changes**: Majority of business in acute care; long-term opportunity for evidence-backed products like Integra Skin. No immediate impact expected.
- **EPS Guidance**: Q3 EPS $0.40-$0.45 reflects extended remediation timelines. Full-year EPS guidance maintained ($2.19-$2.29) due to Q4 recovery and cost management.
- **Shiphold Impact**: $100M full-year impact (up $30M from Q1 guidance) due to extended remediation. No new shipholds expected in H2.
- **Customer Recapture**: Strong demand for Integra Skin post-supply recovery. PriMatrix/SurgiMend relaunch in 2026 targeting $64M pre-recall revenue.
- **ENT Growth**: Q2 below expectations due to reimbursement headwinds. Mid-single-digit growth expected in H2, with long-term confidence in Acclarent portfolio.


Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript

- **Revenue & EPS Guidance**: Full year 2025 revenue $1.65-1.72B, EPS $2.19-2.29. Q2 2025 revenue $390-400M, EPS $0.40-0.45.
- **Compliance Costs**: $55-70M ship holds for 2025 (up from $27M). FDA warning letter actions on track for year-end resolution.
- **Tariff Impact**: $0.22 EPS ($22M) estimated for 2025, with 50% from China tariffs. Mitigation strategies include pricing, sourcing, and exemptions.
- **Operational Transformation**: New leaders (Rick Maveus, Valerie Young) driving program management and supply chain excellence.
- **Private Label Recovery**: H2 2025 step-up of $10M; full year now -low-single-digit vs. prior flat expectation.


**【CEO Opening Remarks】**
- Q1 2025 revenue: $383 million (3.7% reported growth, 3.5% organic decline). Adjusted EPS: $0.41.
- Compliance Master Plan (CMP) progress: 10/14 manufacturing sites assessed; $55-70 million ship holds expected for 2025 (up from $27 million guidance).
- New leadership: Rick Maveus (Transformation & PMO) and Valerie Young (Global Operations & Supply Chain) appointed to drive operational excellence.
- Tariff impact: $22 million ($0.22 EPS) estimated for 2025, with 90-day pause on U.S.-China tariffs.

**【CFO Financial Highlights】**
- Q1 2025 financials: GAAP net loss $11.3M, free cash flow -$40.2M. Gross margin: 62.2% (down 220bps YoY). Adjusted EBITDA: 16.6% (down 290bps YoY).
- Segment performance:
  - CSS: $281M (9.4% reported growth, 1.1% organic decline). Ship holds impacted Advanced Energy, dural access, and neuromonitoring.
  - Tissue Tech: $102M (-9% YoY). Integra Skin production ramping; DuraSorb/UBM growth offset private label delays.
- 2025 guidance: $1.65-1.72B revenue, $2.19-2.29 EPS. Q2 2025: $390-400M revenue, $0.40-0.45 EPS.

**【Q&A Key Takeaways】**
- **Tariff Mitigation**: $0.04 EPS impact in Q2, with 50% from China tariffs. Strategies include pricing, sourcing, and exemptions.
- **Private Label Recovery**: $10M step-up in H2 2025; full year forecast now -low-single-digit vs. prior flat expectation.
- **Compliance Risk**: $28-43M incremental ship holds identified; high-priority FDA actions on track for year-end resolution.
- **Debt Management**: $1.6B net debt (4.3x leverage). Convert maturing in August to be refinanced via revolver; 2026 swap portfolio to fix 50% debt at 3%+.


Integra LifeSciences (IART)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue Recovery**: Q4 2024 revenue up 11.5% YoY to $443M, driven by supply chain recovery and Acclarent integration.
- **Compliance Progress**: 10 workstreams underway in compliance master plan; Braintree facility on track for 2026 H1 SurgiMend production.
- **2025 Outlook**: Full-year revenue $1.65B-$1.72B (2.4%-6.5% growth), adjusted EPS $2.41-$2.51, with 70bps gross margin headwind.
- **Key Risks**: $90M-$120M potential ship hold impacts, Integra Skin production delays, and private label component shortages.
- **Cash Flow Focus**: Free cash flow conversion to improve in 2025, with leverage reduction targeted for 2026.

**【CEO Opening Remarks】**
- Mojdeh Poul emphasized operational challenges, particularly quality and supply chain issues, but highlighted progress in resolving FDA compliance issues. The company is executing a comprehensive compliance master plan with 10 workstreams, including third-party consulting support.
- Key milestones include resuming Integra Skin production at historical levels in Q4 and achieving Braintree facility readiness for 2026 H1 SurgiMend/PriMatrix production.
- 2024 Q4 revenue grew 11.5% YoY to $443M, driven by supply chain recovery and Acclarent integration. Adjusted EPS was $0.97, above guidance.

**【CFO Financial Review】**
- 2024 full-year revenue: $1.61B (+4.5% reported, -1.3% organic). Adjusted EPS: $2.56 (-17.4% YoY) due to supply challenges and compliance investments.
- Q4 gross margin: 65.2% (+50bps YoY). Adjusted EBITDA margin: 23.7% (-160bps YoY). Operating cash flow: $50.7M (Q4) / $129.4M (FY24).
- FY24 organic growth was offset by $90M in supply-related revenue losses, partially mitigated by $95M Acclarent contribution.

**【2025 Financial Guidance】**
- Q1 2025 revenue: $375-385M (1.6%-4.4% reported growth, -6.2% to -3.5% organic). Adjusted EPS: $0.40-$0.45.
- Full-year 2025 revenue: $1.65B-$1.72B (2.4%-6.5% reported growth). Adjusted EPS: $2.41-$2.51.
- Key risks: $90M-$120M potential ship hold impacts, Integra Skin production constraints, and private label component delays.

**【Q&A Key Takeaways】**
- **Integra Skin Supply**: Q1 production constrained by scheduled maintenance and low safety stock; expects normalization by Q2 2025. Demand remains strong due to product uniqueness.
- **Compliance Costs**: 2025 guidance includes 70bps gross margin headwind from compliance master plan. 
- **M&A Strategy**: No immediate M&A focus; prioritizing operational stabilization and debt reduction.
- **Tariff Risk**: No manufacturing in Mexico/Canada, but component sourcing exposure; contingency plans in development.
- **Cash Flow**: Free cash flow conversion expected to improve post-Q3 2024, with leverage reduction in 2026.


IART

IART fundamentals

Earnings Call

You can ask Aime